Seven Fleet Capital Management LP
13F Reported Value
ⓘ$315.1M
Holdings
114
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Seven Fleet Capital Management LP disclosed 114 positions worth $315.1M in its Form 13F-HR for Q1 2026, followed by $TNGX and $RVMD. During the quarter the fund opened 47 new positions and exited 29 — including a new stake in $IPSC and a full exit from $EXEL. The portfolio is most concentrated in Healthcare (56.3% of disclosed assets). All figures are sourced directly from Seven Fleet Capital Management LP’s Form 13F-HR filing with the SEC under CIK 2092021.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
CG ONCOLOGY INC
—Quality
$97.4M1,439,393 sh- 26.9#2,488
Quality
$10.5M502,012 sh - —
Quality
$7.9M80,792 sh - —
Quality
$7.5M195,685 sh - 37.4
Quality
$7.1M187,876 sh - 26.3
Quality
$7.1M209,547 sh - 43.5
Quality
$6.7M2,947,826 sh - —
Quality
$6.4M164,030 sh - —
Quality
$6.3M108,450 sh TANGO THERAPEUTICS INC
—Quality
$6.3M300,648 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| CG ONCOLOGY INC | — | $97.4M | 1,439,393 |
 Tango Therapeutics, Inc.$TNGX | 26.9#2,488 | $10.5M | 502,012 |
 Revolution Medicines, Inc.$RVMD | — | $7.9M | 80,792 |
 Tyra Biosciences, Inc.$TYRA | — | $7.5M | 195,685 |
 Liquidia Corp$LQDA | 37.4 | $7.1M | 187,876 |
 AGIOS PHARMACEUTICALS, INC.$AGIO | 26.3 | $7.1M | 209,547 |
 Century Therapeutics, Inc.$IPSC | 43.5 | $6.7M | 2,947,826 |
 Enliven Therapeutics, Inc.$ELVN | — | $6.4M | 164,030 |
 Vaxcyte, Inc.$PCVX | — | $6.3M | 108,450 |
| TANGO THERAPEUTICS INC | — | $6.3M | 300,648 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Seven Fleet Capital Management LP's 114 positions.
Showing top 10 of 114 holdings.
Sector Allocation
Healthcare
$177.4M
Other
$137.7M
Full Holdings — Seven Fleet Capital Management LP (Q1 2026)
All 114 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | CG ONCOLOGY INC | $97.4M | 30.9% | -5% | — |
| 2 | $TNGX | Tango Therapeutics, Inc. | $10.5M | 3.3% | +133% | 26.9 |
| 3 | $RVMD | Revolution Medicines, Inc. | $7.9M | 2.5% | +23% | — |
| 4 | $TYRA | Tyra Biosciences, Inc. | $7.5M | 2.4% | +146% | — |
| 5 | $LQDA | Liquidia Corp | $7.1M | 2.3% | +106% | 37.4 |
| 6 | $AGIO | AGIOS PHARMACEUTICALS, INC. | $7.1M | 2.3% | +560% | 26.3 |
| 7 | $IPSC | Century Therapeutics, Inc. | $6.7M | 2.1% | NEW | 43.5 |
| 8 | $ELVN | Enliven Therapeutics, Inc. | $6.4M | 2.0% | +1303% | — |
| 9 | $PCVX | Vaxcyte, Inc. | $6.3M | 2.0% | +328% | — |
| 10 | — | TANGO THERAPEUTICS INC | $6.3M | 2.0% | +40% | — |
| 11 |  $COGT | Cogent Biosciences, Inc. | $5.8M | 1.8% | +177% | — |
| 12 | — | AVALO THERAPEUTICS INC | $5.4M | 1.7% | +468% | — |
| 13 | — | MINERVA NEUROSCIENCES INC | $5.4M | 1.7% | NEW | — |
| 14 |  $CGON | CG Oncology, Inc. | $5.1M | 1.6% | -95% | 28 |
| 15 |  $PHVS | Pharvaris N.V. | $4.9M | 1.6% | +212% | — |
| 16 |  $ABVX | Abivax S.A. | $4.8M | 1.5% | NEW | — |
| 17 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.6M | 1.4% | +270% | 26.8 |
| 18 | — | PHARVARIS N V | $4.1M | 1.3% | +160% | — |
| 19 |  $CYTK | CYTOKINETICS INC | $4.0M | 1.3% | +493% | 28 |
| 20 |  $SLNO | SOLENO THERAPEUTICS INC | $3.9M | 1.2% | -11% | 46.3 |
| 21 | — | ENLIVEN THERAPEUTICS INC | $3.7M | 1.2% | +715% | — |
| 22 |  $ERAS | Erasca, Inc. | $3.6M | 1.1% | NEW | — |
| 23 |  $ROIV | Roivant Sciences Ltd. | $3.6M | 1.1% | NEW | — |
| 24 | — | CYTOMX THERAPEUTICS INC. | $3.4M | 1.1% | NEW | — |
| 25 |  $AVTX | Avalo Therapeutics, Inc. | $3.2M | 1.0% | +238% | 4.6 |
| 26 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $3.1M | 1.0% | NEW | — |
| 27 |  $IDYA | IDEAYA Biosciences, Inc. | $2.9M | 0.9% | NEW | 10.5 |
| 28 |  $TSHA | Taysha Gene Therapies, Inc. | $2.8M | 0.9% | +274% | 4.1 |
| 29 |  $ASND | Ascendis Pharma A/S | $2.8M | 0.9% | +115% | 41.5 |
| 30 |  $CMPX | Compass Therapeutics, Inc. | $2.7M | 0.9% | -9% | — |
| 31 |  $DMRA | Damora Therapeutics, Inc. | $2.6M | 0.8% | NEW | — |
| 32 |  $KALV | KalVista Pharmaceuticals, Inc. | $2.6M | 0.8% | +165% | 25.9 |
| 33 |  $RLAY | Relay Therapeutics, Inc. | $2.6M | 0.8% | +253% | 12.7 |
| 34 |  $AXSM | Axsome Therapeutics, Inc. | $2.4M | 0.8% | +8% | 36.6 |
| 35 | — | COMPASS THERAPEUTICS INC | $2.2M | 0.7% | -26% | — |
| 36 | — | DIANTHUS THERAPEUTICS INC | $2.2M | 0.7% | +81% | — |
| 37 | — | EUPRAXIA PHARMACEUTICALS INC | $2.0M | 0.6% | NEW | — |
| 38 |  $DFTX | Definium Therapeutics, Inc. | $1.9M | 0.6% | NEW | — |
| 39 |  $MLYS | Mineralys Therapeutics, Inc. | $1.9M | 0.6% | +356% | — |
| 40 | — | SOLENO THERAPEUTICS INC | $1.8M | 0.6% | -58% | — |
| 41 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $1.8M | 0.6% | +82% | 25.4 |
| 42 |  $CTMX | CytomX Therapeutics, Inc. | $1.7M | 0.6% | +660% | 19.1 |
| 43 |  $LONA | LeonaBio, Inc. | $1.7M | 0.5% | +29% | — |
| 44 |  $SVRA | Savara Inc | $1.6M | 0.5% | +371% | — |
| 45 |  $CATX | Perspective Therapeutics, Inc. | $1.6M | 0.5% | NEW | — |
| 46 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $1.6M | 0.5% | +1201% | 26.6 |
| 47 | — | SAB BIOTHERAPEUTICS INC | $1.5M | 0.5% | NEW | — |
| 48 |  $NERV | Minerva Neurosciences, Inc. | $1.5M | 0.5% | NEW | — |
| 49 |  $ZLAB | Zai Lab Ltd | $1.5M | 0.5% | NEW | — |
| 50 |  $TARS | Tarsus Pharmaceuticals, Inc. | $1.4M | 0.4% | +340% | 40.8 |
| 51 |  $CRVS | Corvus Pharmaceuticals, Inc. | $1.2M | 0.4% | NEW | — |
| 52 | — | VAXCYTE INC | $1.2M | 0.4% | -21% | — |
| 53 |  $AVBP | ArriVent BioPharma, Inc. | $1.2M | 0.4% | NEW | — |
| 54 |  $LRMR | Larimar Therapeutics, Inc. | $1.2M | 0.4% | NEW | — |
| 55 |  $KRYS | Krystal Biotech, Inc. | $1.1M | 0.3% | +8% | 75.9 |
| 56 |  $IVA | Inventiva S.A. | $1.1M | 0.3% | NEW | — |
| 57 |  $LPCN | Lipocine Inc. | $998,287 | 0.3% | NEW | — |
| 58 |  $SYRE | Spyre Therapeutics, Inc. | $993,164 | 0.3% | NEW | — |
| 59 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $975,733 | 0.3% | NEW | 37.2 |
| 60 |  $XNCR | Xencor Inc | $964,800 | 0.3% | -27% | 13.1 |
| 61 |  $CLDX | Celldex Therapeutics, Inc. | $929,396 | 0.3% | NEW | 13.2 |
| 62 |  $REPL | Replimune Group, Inc. | $921,060 | 0.3% | NEW | — |
| 63 |  $MAZE | Maze Therapeutics, Inc. | $916,604 | 0.3% | NEW | 19.7 |
| 64 |  $CLYM | Climb Bio, Inc. | $894,980 | 0.3% | +71% | — |
| 65 |  $CMPS | COMPASS Pathways plc | $873,856 | 0.3% | +295% | — |
| 66 |  $ALKS | Alkermes plc. | $854,651 | 0.3% | NEW | — |
| 67 |  $SLN | Silence Therapeutics plc | $826,120 | 0.3% | +6% | — |
| 68 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $804,601 | 0.3% | +51% | — |
| 69 |  $CELC | Celcuity Inc. | $684,840 | 0.2% | -24% | — |
| 70 |  $ANTX | AN2 Therapeutics, Inc. | $682,977 | 0.2% | NEW | — |
| 71 |  $DNLI | Denali Therapeutics Inc. | $677,491 | 0.2% | NEW | — |
| 72 |  $UTHR | UNITED THERAPEUTICS Corp | $668,881 | 0.2% | -99% | 80.1 |
| 73 |  $LLY | ELI LILLY & Co | $662,234 | 0.2% | NEW | 89.3 |
| 74 |  $VSTM | Verastem, Inc. | $654,020 | 0.2% | +715% | 40.8 |
| 75 | — | LIQUIDIA CORPORATION | $641,580 | 0.2% | -81% | — |
| 76 |  $GERN | GERON CORP | $632,028 | 0.2% | -45% | — |
| 77 |  $IRD | Opus Genetics, Inc. | $610,801 | 0.2% | NEW | — |
| 78 |  $IKT | Inhibikase Therapeutics, Inc. | $547,008 | 0.2% | -39% | — |
| 79 |  $CNTX | Context Therapeutics Inc. | $499,857 | 0.2% | NEW | — |
| 80 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $466,644 | 0.1% | NEW | — |
| 81 |  $VYGR | Voyager Therapeutics, Inc. | $444,684 | 0.1% | NEW | 5.5 |
| 82 |  $GPCR | Structure Therapeutics Inc. | $433,800 | 0.1% | NEW | — |
| 83 |  $PTGX | Protagonist Therapeutics, Inc | $421,600 | 0.1% | -50% | 24.8 |
| 84 | — | PROTHENA CORP PLC | $420,876 | 0.1% | +0% | — |
| 85 |  $NTLA | Intellia Therapeutics, Inc. | $403,830 | 0.1% | NEW | 24.5 |
| 86 |  $MIST | Milestone Pharmaceuticals Inc. | $396,666 | 0.1% | NEW | — |
| 87 |  $SABS | SAB Biotherapeutics, Inc. | $383,000 | 0.1% | NEW | — |
| 88 |  $PALI | PALISADE BIO, INC. | $372,925 | 0.1% | -35% | — |
| 89 |  $GLUE | Monte Rosa Therapeutics, Inc. | $370,619 | 0.1% | +463% | 18.1 |
| 90 |  $EWTX | Edgewise Therapeutics, Inc. | $368,582 | 0.1% | +485% | — |
| 91 |  $UNCY | Unicycive Therapeutics, Inc. | $366,506 | 0.1% | NEW | — |
| 92 |  $CTNM | Contineum Therapeutics, Inc. | $353,325 | 0.1% | NEW | — |
| 93 |  $TRVI | Trevi Therapeutics, Inc. | $323,887 | 0.1% | +282% | — |
| 94 |  $EOLS | Evolus, Inc. | $320,814 | 0.1% | -5% | 30 |
| 95 |  $NKTR | NEKTAR THERAPEUTICS | $309,385 | 0.1% | -71% | 10.2 |
| 96 |  $FULC | Fulcrum Therapeutics, Inc. | $292,227 | 0.1% | NEW | — |
| 97 |  $SEPN | Septerna, Inc. | $275,023 | 0.1% | +0% | 44.6 |
| 98 |  $OCUL | OCULAR THERAPEUTIX, INC | $265,077 | 0.1% | +83% | 12.8 |
| 99 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $257,400 | 0.1% | NEW | — |
| 100 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $231,727 | 0.1% | +44% | — |
| 101 |  $ENTX | Entera Bio Ltd. | $228,152 | 0.1% | +52% | — |
| 102 |  $NUVL | Nuvalent, Inc. | $212,276 | 0.1% | -84% | — |
| 103 |  $BEAM | Beam Therapeutics Inc. | $209,800 | 0.1% | +2512% | 12.1 |
| 104 |  $IRON | Disc Medicine, Inc. | $206,590 | 0.1% | NEW | — |
| 105 |  $WHWK | Whitehawk Therapeutics, Inc. | $187,321 | 0.1% | NEW | 9.6 |
| 106 |  $INBX | Inhibrx Biosciences, Inc. | $166,865 | 0.1% | NEW | 3.1 |
| 107 |  $APGE | Apogee Therapeutics, Inc. | $165,731 | 0.1% | +9% | — |
| 108 |  $CCCC | C4 Therapeutics, Inc. | $150,110 | 0.1% | NEW | 6.5 |
| 109 |  $PMN | ProMIS Neurosciences Inc. | $134,620 | 0.0% | NEW | — |
| 110 | — | TYRA BIOSCIENCES INC | $111,070 | 0.0% | -96% | — |
| 111 |  $PEPG | PepGen Inc. | $105,315 | 0.0% | NEW | — |
| 112 |  $PMVP | PMV Pharmaceuticals, Inc. | $78,738 | 0.0% | +0% | — |
| 113 |  $MGNX | MACROGENICS INC | $38,688 | 0.0% | NEW | 31.7 |
| 114 |  $CGEM | Cullinan Therapeutics, Inc. | $26,203 | 0.0% | -39% | — |
New Positions (47)
$IPSC Century Therapeutics, Inc.$6.7M$ERAS Erasca, Inc.$3.6M$ROIV Roivant Sciences Ltd.$3.6M$EPRX EUPRAXIA PHARMACEUTICALS INC.$3.1M$IDYA IDEAYA Biosciences, Inc.$2.9M$DMRA Damora Therapeutics, Inc.$2.6M$DFTX Definium Therapeutics, Inc.$1.9M$CATX Perspective Therapeutics, Inc.$1.6M$NERV Minerva Neurosciences, Inc.$1.5M$ZLAB Zai Lab Ltd$1.5M$CRVS Corvus Pharmaceuticals, Inc.$1.2MExited Positions (29)
$EXEL EXELIXIS, INC.
$TERN Terns Pharmaceuticals, Inc.
$BLTE BELITE BIO, INC
$DYN Dyne Therapeutics, Inc.
$FOLD AMICUS THERAPEUTICS, INC.
$ZURA Zura Bio Ltd
$PRAX Praxis Precision Medicines, Inc.
$RLMD RELMADA THERAPEUTICS, INC.
$MBX MBX Biosciences, Inc.
$ZYME Zymeworks Inc.
$VRDN Viridian Therapeutics, Inc.\DE
$NRIX Nurix Therapeutics, Inc.
$PLRX PLIANT THERAPEUTICS, INC.
$ACRS Aclaris Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Seven Fleet Capital Management LP including:
Track Seven Fleet Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Seven Fleet Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Seven Fleet Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Seven Fleet Capital Management LP (SEC CIK: 2092021), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Seven Fleet Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.